News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Garner Elizabeth
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2023 |
4
| Garner Elizabeth (Director) has filed a Form 4 on Kezar Life Sciences, Inc.|
Txns:
| Granted 35,000 options to buy
@ $2.64, valued at
$92.4k
|
|
| 06/17/2022 |
4
| Garner Elizabeth (Director) has filed a Form 4 on Kezar Life Sciences, Inc.|
Txns:
| Granted 26,000 options to buy
@ $4.8, valued at
$124.8k
|
|
| 06/30/2021 |
4
| Garner Elizabeth (Director) has filed a Form 4 on Kezar Life Sciences, Inc.|
Txns:
| Granted 26,000 options to buy
@ $5.59, valued at
$145.3k
|
|
| 06/26/2020 |
4
| Garner Elizabeth (Director) has filed a Form 4 on Kezar Life Sciences, Inc.|
Txns:
| Granted 8,896 options to buy
@ $5.6, valued at
$49.8k
|
|
| 12/19/2019 |
4
| Garner Elizabeth (Director) has filed a Form 4 on Kezar Life Sciences, Inc.|
Txns:
| Granted 17,793 options to buy
@ $3.03, valued at
$53.9k
|
|
| 12/19/2019 |
3
| Garner Elizabeth (Director) has filed a Form 3 on Kezar Life Sciences, Inc. |
| 01/31/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/28/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/21/2018 |
4
| Garner Elizabeth (Sr. VP & Chief Medical Officer) has filed a Form 4 on AGILE THERAPEUTICS INC|
Txns:
| Granted 150,000 options to buy
@ $0.58, valued at
$87k
|
|
| 01/26/2018 |
4
| Garner Elizabeth (Sr. VP & Chief Medical Officer) has filed a Form 4 on AGILE THERAPEUTICS INC|
Txns:
| Paid exercise price by delivering 5,765 shares
@ $3.32, valued at
$19.1k
Granted 107,000 options to buy
@ $3.46, valued at
$370.2k
Granted 18,565 restricted stock units
@ $0
Exercised 17,500 restricted stock units
@ $0 |
|
| 01/27/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 02/10/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|
|